A detailed history of Vanguard Group Inc transactions in Rallybio Corp stock. As of the latest transaction made, Vanguard Group Inc holds 925,521 shares of RLYB stock, worth $795,948. This represents 0.0% of its overall portfolio holdings.

Number of Shares
925,521
Previous 857,896 7.88%
Holding current value
$795,948
Previous $1.15 Million 5.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.09 - $1.45 $73,711 - $98,056
67,625 Added 7.88%
925,521 $1.08 Million
Q2 2024

Aug 13, 2024

SELL
$1.34 - $2.98 $293,292 - $652,247
-218,875 Reduced 20.33%
857,896 $1.15 Million
Q1 2024

May 10, 2024

BUY
$1.25 - $2.4 $16,001 - $30,722
12,801 Added 1.2%
1,076,771 $1.99 Million
Q4 2023

Feb 14, 2024

BUY
$1.91 - $4.39 $27,005 - $62,070
14,139 Added 1.35%
1,063,970 $2.54 Million
Q3 2023

Nov 14, 2023

BUY
$3.37 - $6.16 $39,462 - $72,133
11,710 Added 1.13%
1,049,831 $3.54 Million
Q2 2023

Aug 14, 2023

BUY
$4.31 - $8.89 $185,765 - $383,167
43,101 Added 4.33%
1,038,121 $5.88 Million
Q1 2023

May 15, 2023

BUY
$4.37 - $8.75 $115,009 - $230,282
26,318 Added 2.72%
995,020 $5.68 Million
Q4 2022

Feb 10, 2023

BUY
$4.67 - $14.86 $794,208 - $2.53 Million
170,066 Added 21.29%
968,702 $6.36 Million
Q3 2022

Nov 14, 2022

BUY
$7.54 - $14.56 $770,037 - $1.49 Million
102,127 Added 14.66%
798,636 $11.6 Million
Q2 2022

Aug 12, 2022

SELL
$6.26 - $13.65 $84,760 - $184,821
-13,540 Reduced 1.91%
696,509 $5.26 Million
Q1 2022

May 13, 2022

BUY
$6.91 - $15.04 $2.7 Million - $5.87 Million
390,170 Added 121.97%
710,049 $4.96 Million
Q4 2021

Feb 14, 2022

SELL
$9.3 - $19.91 $658,551 - $1.41 Million
-70,812 Reduced 18.12%
319,879 $3.05 Million
Q3 2021

Nov 12, 2021

BUY
$10.83 - $23.4 $4.23 Million - $9.14 Million
390,691 New
390,691 $6.87 Million

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $27.6M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.